Palbociclib

Introduction Overview

Generic Name

palbociclib

Brand Name

Ibrance

Dosage Form

oral tablet, oral capsule

Drug Class

CDK 4/6 inhibitors

Pharmacokinetics

Absorption:
Palbociclib is administered orally and exhibits good absorption from the gastrointestinal tract. After oral administration, palbociclib reaches peak plasma concentrations (Cmax) approximately 6-12 hours post-dose. Although food intake does not significantly affect the extent of absorption, administration with food can delay Tmax and increase AUC (area under the curve) slightly, which does not necessitate dose adjustments. The absolute bioavailability of palbociclib has been reported to be around 46%, indicating moderate oral availability. The drug demonstrates nonlinear pharmacokinetics at high doses due to limited solubility but is generally dose-proportional within therapeutic ranges.

Distribution:
Palbociclib exhibits extensive distribution throughout the body, with a volume of distribution (Vd) estimated to be approximately 2580 liters, indicating extensive tissue binding. Palbociclib is highly protein bound (~85%), primarily to albumin, which affects its free plasma concentration and pharmacodynamics. The ability of palbociclib to distribute into tissues is pivotal for its anticancer activity, targeting tumor cell populations effectively. Studies suggest that palbociclib can cross plasma membranes but does not significantly cross the blood-brain barrier, limiting central nervous system exposure. Distribution may be influenced by co-administration of other drugs that compete for protein binding or affect transporters.

Metabolism:
Palbociclib undergoes hepatic metabolism primarily via cytochrome P450 enzyme CYP3A4, responsible for its oxidative metabolism. Minor contributions come from sulfotransferase enzymes. Metabolic transformation results in several metabolites, mostly inactive, with only palbociclib and a few metabolites detected at significant circulating levels. Given its CYP3A4 metabolism, palbociclib's exposure can be significantly altered by co-administration of CYP3A inhibitors or inducers, necessitating dose adjustments or avoidance of certain drug combinations. The drug itself does not strongly induce or inhibit CYP enzymes but careful monitoring is required during concomitant therapy.

Elimination:
Palbociclib is primarily eliminated via feces (approximately 74%) with renal excretion accounting for about 17% of elimination, mostly as unchanged drug or metabolites. The terminal half-life is approximately 29 hours, supporting a once-daily dosing regimen. Clearance is influenced by hepatic function, and patients with moderate hepatic impairment may require dose adjustments. The drug's elimination profile allows intermittent dosing (21 days on treatment followed by 7 days off), which helps manage toxicity, especially hematological side effects. The steady-state concentrations are typically achieved after 8 days of once-daily dosing.

Dosage Forms

Available Dosage Forms:
Ibrance is commercially available as oral capsules and oral tablets in specific strengths. The capsule formulations typically include 75 mg, 100 mg, and 125 mg strengths. Tablets are also available in corresponding strengths depending on regional approvals and formulation specifics. The capsules contain inactive ingredients such as microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, succinic acid, hypromellose, titanium dioxide, triacetin, and colorants (red iron oxide for 75 mg and 125 mg, yellow iron oxide for 100 mg).

Dosages for Adults and Adolescents:
The recommended initial dosing regimen for palbociclib in adults with HR-positive, HER2-negative advanced or metastatic breast cancer is 125 mg taken orally once daily with or without food for 21 consecutive days followed by 7 days off treatment to complete a 28-day cycle. Dose modifications may be made based on tolerance, especially for hematologic toxicities such as neutropenia. In patients intolerant to the starting dose, dose reductions can be made in 25 mg decrements (to 100 mg and then to 75 mg). The dosing schedule is intended to be combined with an aromatase inhibitor or fulvestrant depending on prior therapy and patient profile.

Specific Patient Populations:
In patients with hepatic impairment, dose adjustments are recommended since palbociclib metabolism is hepatic and exposure can be increased. Moderate hepatic impairment necessitates cautious dosing or dose reduction; no established dosing exists for severe impairment as safety has not been studied extensively. Renal impairment does not significantly affect palbociclib pharmacokinetics; thus, no dose adjustment is required for mild to moderate renal impairment. The drug is not indicated or studied in pediatric populations; safety and efficacy have not been established in children. Careful monitoring is advised in elderly patients or those with comorbidities due to altered drug clearance and increased risk of adverse effects.

Mechanism Of Action

Ibrance (palbociclib) is a selective, reversible inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are pivotal regulators of cell cycle progression through the G1 to S phase transition. By inhibiting the kinase activity of CDK4/6, palbociclib prevents the phosphorylation of the retinoblastoma (Rb) protein. Hypophosphorylated Rb binds E2F transcription factors tightly, inhibiting transcription of genes essential for DNA synthesis and S-phase entry, effectively causing G1 cell cycle arrest.

This mechanism is particularly relevant in hormone receptor-positive (HR+) breast cancer, where tumor cells often demonstrate dysregulation or hyperactivation of the cyclin D-CDK4/6-Rb pathway, leading to unchecked proliferation. By blocking CDK4/6 activity, Ibrance halts tumor cell growth and proliferation, rendering cancer cells more susceptible to endocrine therapies like aromatase inhibitors or fulvestrant.

On a cellular signaling level, palbociclib enforces cell cycle arrest without inducing apoptosis directly. Its antiproliferative effect synergizes with hormonal therapies by overcoming resistance mechanisms that cancer cells develop. This synergism delays cancer progression and improves clinical outcomes as demonstrated in multiple phase III clinical trials.

Comparatively, other CDK4/6 inhibitors, such as ribociclib and abemaciclib, share a similar mechanism but exhibit differences in potency, selectivity, and side effect profiles. Research continues to explore differences in efficacy and toxicity, with palbociclib having a well-characterized profile in HR+ metastatic breast cancer. Clinical studies show improved progression-free survival and extended overall survival when Ibrance is combined with endocrine therapies, solidifying its role as a targeted therapy that interferes with the fundamental cell cycle machinery in breast cancer cells.

Pharmacological Actions

Selective inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), key regulators of the G1-S phase cell cycle transition.
Induction of G1 cell cycle arrest in HR-positive breast cancer cells by inhibiting phosphorylation of the retinoblastoma (Rb) protein.
Suppression of tumor cell proliferation by halting progression through the cell cycle.
Synergistic enhancement of endocrine therapy efficacy through overcoming hormone therapy resistance mechanisms.
Reduction of tumor growth and metastasis in hormone receptor-positive, HER2-negative breast cancer.
Targeted mechanism distinct from cytotoxic chemotherapy, allowing selective antiproliferative effects with a more favorable side effect profile.
Modulation of gene transcription relevant to DNA synthesis by preventing release of E2F transcription factors.
No direct induction of apoptosis, but long-term cell cycle arrest may promote programmed cell death.
Oral administration allows for convenient dosing and improved patient compliance.
Capacity to improve progression-free and overall survival in clinical trials when used with aromatase inhibitors or fulvestrant.
Minimal off-target kinase inhibition, enhancing safety and tolerability.
Metabolized primarily by CYP3A4, influencing drug interaction profiles.
Potential to cause hematological side effects predominantly neutropenia due to effects on proliferating bone marrow progenitors.

Therapeutic Or Clinical Uses

Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women and men.
In combination with fulvestrant for patients with disease progression following endocrine therapy.
Part of targeted therapy regimens designed to delay cancer progression by inhibiting cell cycle kinases.
Delays tumor growth and metastasis in HR+/HER2− breast cancer subtypes.
Used to improve progression-free survival in metastatic breast cancer.
Indicated for use in postmenopausal women and men with advanced breast cancer.
Employs oral administration allowing outpatient treatment settings.
Sometimes employed sequentially following resistance or intolerance to hormone monotherapy.
Investigated in clinical trials for combination with other targeted therapies.
Contributes to overall survival extension when combined with endocrine therapy.
Serves as an alternative to chemotherapy in specific breast cancer settings.
Integral in managing luminal breast cancer phenotypes dependent on CDK4/6 pathway.
Used in patients with HR-positive advanced breast cancer who require systemic therapy.

Side Or Adverse Effects

Neutropenia (low white blood cell counts), which increases risk of serious infections.
Fatigue and tiredness, often reported during treatment cycles.
Nausea and occasional vomiting.
Diarrhea, sometimes requiring supportive care.
Oral mucositis such as sore mouth or stomatitis symptoms.
Elevated liver enzymes indicating liver function abnormalities.
Hair thinning or hair loss (alopecia), more commonly hair thinning.
Rash or skin eruptions in some patients.
Loss of appetite leading to weight concerns.
Low platelet counts (thrombocytopenia), resulting in bleeding risk.
Anemia (low red blood cell counts), causing weakness and dizziness.
Potential for pulmonary toxicity including pneumonitis and interstitial lung disease.
Infections secondary to immunosuppression from neutropenia.
Possible fertility impairment in males affecting reproductive capability.
Gastrointestinal disturbances such as abdominal pain and constipation.

Precautions

Monitor complete blood counts regularly to detect neutropenia early.
Assess liver function periodically due to risk of hepatotoxicity.
Use effective contraception in females of reproductive potential during treatment and for at least 3 weeks post-therapy.
Male patients with female partners of reproductive potential should use birth control during treatment and for 3 months after the last dose.
Avoid grapefruit and grapefruit products to prevent increased drug exposure.
Careful dose modification or interruption in case of severe hematologic toxicities.
Vigilance for signs of infection and prompt management if neutropenia occurs.
Monitor for respiratory symptoms indicative of lung inflammation or pneumonitis.
Consider dose adjustments in patients with moderate hepatic impairment.
Not studied in pediatric patients; safety and efficacy unknown in children.
Use caution in patients with existing liver or kidney dysfunction.
Educate patients on recognizing symptoms of low blood counts such as dizziness, shortness of breath, or unusual bleeding.
Avoid concomitant strong CYP3A inhibitors or inducers without provider consultation.
Regularly review all concomitant medications for potential interactions.
Do not chew, crush, or open capsules to avoid altered pharmacokinetics.

Warnings

Severe neutropenia may result in life-threatening infections; monitoring is essential.
Potential for serious pulmonary toxicity including pneumonitis, which may be fatal if untreated.
Not established as safe or effective in pediatric populations; risk unknown.
Potential teratogenicity and fetal harm; pregnancy must be avoided during treatment.
Breastfeeding is contraindicated during treatment and for 3 weeks after last dose.
Risk of impaired male fertility; discuss family planning before treatment initiation.
Serious infections secondary to immunosuppression may require hospitalization.
Use with strong CYP3A inhibitors may raise palbociclib plasma levels significantly, increasing toxicity risk.
Avoid abrupt cessation of therapy without consulting healthcare provider to prevent disease progression.
Patients should be advised to report any symptoms of fever, chills, cough, or unexplained bruising immediately.
Dose interruptions or reductions may be necessary to manage toxicity.
Risk of hepatotoxicity and elevated liver enzymes; monitor liver function tests systematically.
Potential interactions with numerous medications necessitate thorough drug interaction assessment.
Gastrointestinal toxicity may require supportive care to maintain adherence.
Concomitant use with other myelosuppressive agents may exacerbate hematologic adverse effects.

Contraindication

Known hypersensitivity to palbociclib or any components of the formulation.
Patients with prior severe allergic reaction to any CDK4/6 inhibitor.
Concurrent use with strong CYP3A inhibitors or inducers unless dose adjustments can be safely administered.
Pregnancy due to known teratogenic effects.
Breastfeeding females as safety for the infant is unknown and drug passage into milk is possible.
Patients with severe hepatic impairment where safety has not been established.
Use contraindicated in patients with uncontrolled infections or sepsis at treatment initiation.
Not indicated for use in ER/PgR-negative breast cancer or HER2-positive breast cancer as monotherapy.
Not approved for treatment outside of HR-positive, HER2-negative advanced breast cancer.
Patients with active pulmonary infections or significant lung disease should be evaluated carefully prior to therapy.
Concurrent participation in another investigational drug study without clearance.
Use avoided in patients with known congenital long QT syndrome if QT prolongation risk is present.
Patients with severely compromised bone marrow function or history of aplastic anemia.
Known severe hypersensitivity to any compounds containing iron oxides or colorants used in tablets.
Absolute contraindications include those outlined by FDA-approved labeling where risk outweighs benefit.

Drug Interactions

CYP3A inhibitors such as clarithromycin, ketoconazole, diltiazem, erythromycin, fluconazole, and verapamil can significantly increase palbociclib plasma concentrations and raise toxicity risk.
CYP3A inducers including rifampin, phenytoin, carbamazepine, phenobarbital, and glucocorticoids reduce palbociclib exposure, possibly decreasing efficacy.
Concomitant use with CYP3A substrates with narrow therapeutic indices (e.g., cyclosporine, some tricyclic antidepressants) may require dose adjustments.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A and increase palbociclib plasma concentration excessively.
Combination with strong CYP3A inhibitors contraindicates standard dosing; dose alterations or interruption necessary.
Potential pharmacodynamic interaction with other myelosuppressive drugs increasing hematological adverse events.
Possible interaction with hormonal therapies (aromatase inhibitors and fulvestrant) which requires coordinated administration but no major metabolic interaction.
Drugs affecting P-glycoprotein or other drug transporters may alter palbociclib cellular distribution.
Concurrent use with anticoagulants may necessitate monitoring due to thrombocytopenia risk.
Caution is advised when used with drugs causing QT prolongation, although palbociclib’s risk is low.
Interaction with strong acid suppressants not observed; palbociclib absorption not pH dependent.
Dose modification guidelines exist when co-administered with inhibitors or inducers of CYP3A4; clinical monitoring required.
Herbal supplements like St. John's Wort may induce CYP3A and reduce palbociclib effectiveness.
Concurrent use with live vaccines is not recommended during treatment due to immunosuppression.
Assessment of complete medication lists is critical due to extensive CYP3A metabolism.

Preparations Of The Drug

Oral capsules in strengths of 75 mg, 100 mg, and 125 mg containing palbociclib as active ingredient.
Oral tablets containing 75 mg, 100 mg, and 125 mg palbociclib, formulated for once daily administration.
Capsules and tablets contain inactive ingredients including microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, titanium dioxide, triacetin, succinic acid, and FD&C Blue #2/Indigo Carmine aluminum lake for tablets.
Capsule versions include red iron oxide (75 mg, 125 mg) or yellow iron oxide (100 mg) for coloration.
Packaged as blister packs to protect from moisture and maintain stability during storage.
Manufactured by Pfizer Labs, ensuring compliance with Good Manufacturing Practices (GMP).
Packaged for oral administration with instructions for swallowing whole without crushing or chewing.
Stable at room temperature (68°F to 77°F or 20°C to 25°C) and kept in the original blister pack for preservation.
Formulations designed for consistent bioavailability with dosing convenience.
Available commercially under the brand name Ibrance and also as generic palbociclib in capsule form.
Pre-packaged dosing kits may be available in specialty pharmacies for cycle-based treatment.
Instructions include avoidance of broken, cracked, or damaged capsules or tablets.
Each preparation includes patient information leaflets detailing administration instructions and side effects.
Packaging and formulation minimize light exposure and moisture to maintain drug integrity.
Available through prescription only with appropriate oncologist supervision.